Propella Therapeutics, Inc. announced nonclinical data for its lead product candidate, PRL-02, will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium. PRL-02 is being evaluated in an ongoing Phase 1 study for patients with advanced prostate cancer; the recommended phase 2 dose will be selected in Q1 2022 based upon pharmacokinetic, safety, clinical pharmacology, and efficacy results.
Propella Therapeutics, Inc. will be participating in the American Society of Clinical Oncology Genitourinary Cancers Symposium from February 17-19, 2022.
Propella Therapeutics, Inc. participated in the 40th Annual J.P. Morgan Healthcare Conference from January 10–13, 2022.
Propella Therapeutics, Inc. participated in the 11th Annual LifeSci Partners Corporate Access Event from January 5-7, 2022.
Propella Therapeutics, Inc. presented at the MedInvest Oncology Conference on December 7, 2021.
Propella Therapeutics, Inc., a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.